Prothena Announces First Human Dosed in Phase 1 Study of PRX003 (Treatment of Inflammatory Diseases)

[Bob]

It's only news about a phase 1 study (for a monoclonal antibody) which means that the drug is more than likely never to reach the market, but i thought it might be of interest for some people anyway...

Prothena Announces First Human Dosed in Phase 1 Study of PRX003 for the Treatment of Psoriasis and Other Inflammatory Diseases
June 9 2015
http://money.cnn.com/news/newsfeeds/articles/globenewswire/10137588.htm

About PRX003

PRX003 is a monoclonal antibody for the potential treatment of psoriasis and other inflammatory diseases. Within the immune system, Th-17 white blood cells initiate the body's response to infections, and are known to be a key participant in both normal inflammatory reactions and autoimmune diseases. MCAM is expressed on the surface of Th-17 cells, and allows certain cells traveling in the blood stream to leave the circulation and enter tissues, primarily to initiate or continue a disease process. PRX003 is designed to block MCAM and not allow the migration of these pathogenic cells into tissues. PRX003 may be useful for treating a variety of inflammatory diseases such as psoriasis, psoriatic arthritis, rheumatoid arthritis, multiple sclerosis, sarcoidosis, uveitis, vasculitis, and Behcet's disease. For more information about the ongoing Phase 1 clinical study of PRX003, please visit www.clinicaltrials.gov and search identifier NCT02458677.